Chrisanna Dobrowolski, Shu Min Lao, Fadi Kharouf, Paula Parnizari Croci, Joan Wither, Dafna D Gladman, Laura Whitall Garcia, Arenn Jauhal, Zahi Touma
{"title":"Lupus nephritis II: Treatment and monitoring.","authors":"Chrisanna Dobrowolski, Shu Min Lao, Fadi Kharouf, Paula Parnizari Croci, Joan Wither, Dafna D Gladman, Laura Whitall Garcia, Arenn Jauhal, Zahi Touma","doi":"10.1016/bs.acc.2025.01.001","DOIUrl":null,"url":null,"abstract":"<p><p>Renal involvement in systemic lupus erythematosus (SLE), lupus nephritis (LN), is common and can result in significant morbidity, including progressive renal dysfunction, and even ultimately leading to death. LN is heterogeneous complicated by the immunologic component, and it is critical to accurately classify LN to direct optimal therapy. Accordingly, identification of objective markers is paramount in reflecting disease stage and monitoring treatment response. In part two of this series, we comprehensively examine LN disease classification, therapies and potential markers to guide therapeutic options.</p>","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"126 ","pages":"121-154"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in clinical chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/bs.acc.2025.01.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/19 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Renal involvement in systemic lupus erythematosus (SLE), lupus nephritis (LN), is common and can result in significant morbidity, including progressive renal dysfunction, and even ultimately leading to death. LN is heterogeneous complicated by the immunologic component, and it is critical to accurately classify LN to direct optimal therapy. Accordingly, identification of objective markers is paramount in reflecting disease stage and monitoring treatment response. In part two of this series, we comprehensively examine LN disease classification, therapies and potential markers to guide therapeutic options.